Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-25T01:37:36.169Z Has data issue: false hasContentIssue false
  • English
  • Français

Antiepileptic Drugs in the 21st Century

Published online by Cambridge University Press:  07 November 2014

Carl W. Bazil
Get access Rights & Permissions [Opens in a new window]

Abstract

During the past 10 years, there has been a welcome influx of novel agents for the treatment of epilepsy. Many show advantages compared to older agents, including better adverse effect profiles and lack of drug-drug interactions. The sheer number of agents now available makes distinction among them confusing at times. Agents differ in spectrum of action, pharmacokinetic profile (affecting dosing schedule and drug interactions), and titration time. This review highlights the differences between the various new agents and the more traditional antiseizure drugs. Evidence for the widespread use of these compounds outside their indication, particularly for diseases other than epilepsy, is reviewed as well.

Type
Feature Articles
Information
CNS Spectrums , Volume 6 , Issue 9: Epilepsy: Diagnosis and Treatment in the 21st Century , September 2001 , pp. 756 - 765
Copyright
Copyright © Cambridge University Press 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. DeLorenzo, RJ. Phenytoin: mechanisms of action. In: Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven; 1995:271Google Scholar
2. Bialer, M, Johannessen, SI, Kupferberg, HJ, Levy, RH, Loiseau, P, Perucca, E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. 1999;34:1–41.Google Scholar
3. Brodie, MJ, Dichter, MA. Antiepileptic drugs. New Engl J Med. 1996;334:168–175.Google Scholar
4. Brodie, MJ, Richens, A, Yuen, AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345:476–479.Google Scholar
5. Tennis, P, Stern, RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49:542–546.Google Scholar
6. Mattson, RH. Carbamazepine. In: Engel, J, Pedley, TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, Pa: Lippincott-Raven; 1997:1491–1502.Google Scholar
7. Naritoku, DK, Mueed, S. Intravenous loading of valproate for epilepsy. Clin Neuropharmol. 1999;2:102–106.Google Scholar
8. Venkataraman, V, Wheless, JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res. 1999;35:147–153.Google Scholar
9. Dreifuss, FE, Santilli, N, Langer, DH, Sweeney, KP, Moline, KA, Menander, KB. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379–385.Google Scholar
10. Isojarvi, JIT, Laatikainen, TJ, Pakarinen, AJ, Juntunen, KTS, Myllyla, VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1383–1388.Google Scholar
11. Rowan, AJ. Valproate. In: Engel, J, Pedley, TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, Pa: Lippincott-Raven; 1997:1599–1607.Google Scholar
12. Kelly, KM, Gross, RA, MacDonald, RL. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett. 1990;116:233–238.Google Scholar
13. Herman, ST, Pedley, TA. New options for the treatment of epilepsy. JAMA. 1998;280:693–694.Google Scholar
14. Gidal, BE, DeCerce, J, Bockbrader, HN et al. , Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31:91–99.Google Scholar
15. Leach, MJ, Marden, CM, Miller, AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia. 1986;27:490–497.Google Scholar
16. Brodie, MJ. Lamotrigine. Lancet. 1992;339:1397–1400.Google Scholar
17. Dichter, MA, Brodie, MJ. New antiepileptic drugs. N Engl J Med. 1996;334:1583–1590.Google Scholar
18. Schlienger, RG, Shapiro, LE, Shear, NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia. 1998;39:S22–S26.Google Scholar
19. White, HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 1997;38(suppl 1):S9–S17.Google Scholar
20. Shorvon, SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(suppl 2):S18–S22.Google Scholar
21. Eckardt, KM, Steinhoff, BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia. 1998;39:671–674.Google Scholar
22. Cereghino, JJ, Biton, VB, Abou-Khalil, B et al. , Levetiracetatn for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236–242.Google Scholar
23. Van Parys, JAP, Meinardi, H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on named-patient basis. Epilepsy Res. 1994;19:79–85.Google Scholar
24. Rock, DM, Macdonald, RL, Taylor, CP. Blockade of sustained repetitive action potentials in cultures of spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 1989;3:138–143.Google Scholar
25. Bazil, CW, Pedley, TA. Advances in the medical treatment of epilepsy. Rev Contemp Pharmacother. 1998;49:135–162.Google Scholar
26. Okada, M, Kaneko, S, Hirano, T et al. , Effects of zonisamide on dopaminergic systems. Epilepsy Res. 1995;22:193–205.Google Scholar
27. Leppik, IE, Willmore, LJ, Homan, RW et al. , Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 1993;14:165–173.Google Scholar
28. Mattson, RH, Cramer, JA, Collins, JF et al. , A comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145–151.Google Scholar
29. Mattson, RH, Cramer, JA, Collins, JF. Comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med. 1992;327:765–771.Google Scholar
30. Marson, AG, Kadir, ZA, Hutton, JL, Chadwick, DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 1997;38:859–880.Google Scholar
31. Bill, PA, Vigonius, U, Pohlmann, H et al. , A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195–204.Google Scholar
32. Guerreiro, MM, Vigonius, U, Pohlmann, H et al. , A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205–213.Google Scholar
33. Reinikainen, KJ, Keranen, T, Halonen, T, Komulainen, H, Riekkinen, PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. 1987;1:284–289.Google Scholar
34. Christe, W, Kramer, G, Vigonius, U et al. , A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26:451–460.Google Scholar
35. Lindberger, M, Alenius, M, Frisen, L et al. , Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. Epilepsia. 2000;41:1289–1295.Google Scholar
36. Brodie, MJ, Richens, A, Yuen, AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345:476–479.Google Scholar
37. Steiner, TJ, Dellaportas, CI, Findley, LJ et al. , Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 1999;40:601–607.Google Scholar
38. Perucca, E, Gram, L, Avanzini, G, Dulac, O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39:5–17.CrossRefGoogle Scholar
39. Kalter, H, Warkany, J. Congenital malformations. N Engl J Med. 1983;308:491–497.Google Scholar
40. Kelly, TE. Teratogenicity of anticonvulsant drugs I: review of the literature. Am J Med Genet. 1984;19:413–434.Google Scholar
41. Yerby, MS, Collins, SD. Teratogenicity of antiepileptic drugs. In: Engel, J, Pedley, TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, Pa: Lippincott-Raven; 1997:1195–1203.Google Scholar
42. Morrell, MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37(suppl 6):S34–S44.CrossRefGoogle Scholar
43. Placidi, GF, Lenzi, A, Lazzerini, F et al. , The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry. 1986;47:490–494.Google Scholar
44. Ross, EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology. 2000;55(suppl 1):S41–S46.Google Scholar
45. Backonja, M, Beydoun, A, Edwards, KR et al. , Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998;280:1831–1836.Google Scholar
46. Rowbotham, M, Harden, N, Stacey, B et al. , Gabapentin for the treatment of postherpeutic neuralgia. JAMA. 1998;280:1837–1842.Google Scholar
47. Pande, AC, Davidson, JRT, Jefferson, JW et al. , Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19:341–348.Google Scholar
48. Pande, AC, Pollack, MH, Crockatt, J et al. , Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467–471.Google Scholar
49. Pande, AC, Crockatt, JG, Janney, CA et al. , Gabapentin in bipolar disorder a placebo-controlled trial of adjunctive therapy. Bipolar Disord. 2000;2:249–255.Google Scholar
50. Vestergaard, K, Andersen, G, Gottrup, H, Kristensen, BT, Jensen, TS. Lamotrigine for central poststroke pain. Neurology. 2001;56:184–190.Google Scholar
51. Simpson, DM, Olney, R, McArthur, JC, Khan, A, Godbold, J, Ebel-Frommer, K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115–2119.Google Scholar
52. Calabrese, JR, Bowden, CL, Sachs, GS et al. , A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;60:79–88.Google Scholar
53. Zvartau-Hind, M, Din, MU, Gilani, A, Lisak, RP, Khan, OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55:1587–1588.Google Scholar
54. Placidi, F, Diomedi, M, Marciani, MG, Romigi, A, Gigli, GL. Effects of anticonvulsants on nocturnal sleep in epilepsy. Neurology. 2000;54(suppl 1):S25–S32.Google Scholar